Stockscreener 앱 받기
1.04
0.00%
0.00
시간 외 거래:
1.04
전일 마감가:
$1.04
열려 있는:
$1.04
하루 거래량:
59,894
Relative Volume:
0.52
시가총액:
$24.36M
수익:
-
순이익/손실:
$-22.29M
주가수익비율:
-0.8814
EPS:
-1.18
순현금흐름:
$-17.12M
1주 성능:
+0.97%
1개월 성능:
+17.12%
6개월 성능:
-19.07%
1년 성능:
-35.80%
1일 변동 폭
$1.0272
$1.06
1주일 범위
$0.9974
$1.07
52주 변동 폭
$0.8101
$1.76
엔라이벡스 Stock (ENLV) Company Profile
ENLV을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ENLV
Enlivex Therapeutics Ltd
|
1.04 | 24.36M | 0 | -22.29M | -17.12M | -1.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
엔라이벡스 Stock (ENLV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-03-02 | 재확인 | H.C. Wainwright | Buy |
엔라이벡스 주식(ENLV)의 최신 뉴스
Enlivex Receives Regulatory Authorization From Israel’s Health Ministry For The Initiation Of Phase 1/2 Trial Evaluating Allocetra In Patients With Knee Osteoarthritis - ACCESS Newswire
Enlivex Receives Notice of Allowance for U.S. Patent Application Covering Methods of Treating Sepsis with Allocetra™ - Barchart.com
Enlivex stock holds Buy rating with $7 target from H.C. Wainwright - Investing.com India
Enlivex Therapeutics to Showcase Allocetra's Potential in Osteoa - GuruFocus
Enlivex to Present Allocetra™ Insights at OARSI 2025 - TipRanks
Enlivex Therapeutics to Showcase Allocetra's Potential in Osteoarthritis at OARSI 2025 World Congress - The Manila Times
Enlivex Therapeutics to Showcase Allocetra’s Potential in Osteoarthritis at OARSI 2025 World - Bluefield Daily Telegraph
Enlivex Therapeutics to Showcase Allocetra’s Potential in Osteoarthritis at OARSI 2025 World Congress - TradingView
Enlivex enrols all patients in Phase II stage of knee osteoarthritis trial - Yahoo
Enlivex Therapeutics (NASDAQ:ENLV) Given “Buy” Rating at D. Boral Capital - Defense World
Enlivex (ENLV) Completes Patient Enrollment for Phase II Allocetra Trial | ENLV Stock News - GuruFocus
Enlivex Completes Phase II Enrollment for Osteoarthritis Trial - TipRanks
Enlivex Announces Completion of Enrollment In The Phase II stage Of Its Phase I/II Trial Evaluating Allocetra In Patients With Moderate To Severe Knee Osteoarthritis - The Manila Times
Enlivex Announces Completion of Enrollment In The Phase II stage Of Its Phase I/II Trial Evaluating Allocetra In Patients With Moderate To Severe Knee Osteoarthritis | ENLV Stock News - GuruFocus
Enlivex Therapeutics Completes Patient Enrollment in Phase II Trial of Allocetra™ for Knee Osteoarthritis - Nasdaq
Major Milestone: 133-Patient Phase II Trial Completed for Revolutionary Knee Osteoarthritis Treatment Allocetra - Stock Titan
Is Enlivex Therapeutics (NASDAQ:ENLV) In A Good Position To Invest In Growth? - Yahoo Finance
D. Boral Capital Reaffirms “Buy” Rating for Enlivex Therapeutics (NASDAQ:ENLV) - Defense World
Enlivex Begins Phase I Trial for TMJ Osteoarthritis Treatment - TipRanks
Enlivex Announces the Dosing of the First Patient in a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis - The Manila Times
Groundbreaking TMJ Treatment Trial Begins: Enlivex Targets Major Medical Need - Stock Titan
Enlivex Therapeutics Releases 2024 Financial Statements - TipRanks
Enlivex Therapeutics (ENLV) to Release Quarterly Earnings on Friday - Defense World
HC Wainwright Has Negative Estimate for ENLV FY2025 Earnings - Defense World
HC Wainwright Forecasts Strong Price Appreciation for Enlivex Therapeutics (NASDAQ:ENLV) Stock - The AM Reporter
Enlivex Therapeutics (NASDAQ:ENLV) Given New $7.00 Price Target at HC Wainwright - Defense World
Enlivex stock price target raised to $7 at H.C. Wainwright By Investing.com - Investing.com South Africa
Enlivex stock price target raised to $7 at H.C. Wainwright - Investing.com India
Enlivex Secures Chinese Patent Allowance for Osteoarthritis Treatment - TipRanks
Enlivex Receives Notice of Allowance for Chinese Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis - The Manila Times
Enlivex Therapeutics Secures Patent Allowance in China for Allocetra™ as Treatment for Osteoarthritis - Nasdaq
Breakthrough: Enlivex's Arthritis Drug Cuts Pain by 47%, Secures Major China Patent Win - StockTitan
Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Short Interest Update - Defense World
IOBT To Report Melanoma Trial Data In Q3, NPCE Eyes 15-20% Revenue Growth For 2025, DXR On Watch - RTTNews
Enlivex Therapeutics Announces Investor Webinar to Discuss Positive Interim Data from Phase I/II Allocetra™ Trial in Knee Osteoarthritis - The Manila Times
Enlivex Reports Promising Interim Results in Osteoarthritis Trial - TipRanks
Enlivex Therapeutics Announces Investor Webinar To Discuss Positive Interim Data From Phase I/Ii Allocetra(TM) Trial In Knee Osteoarthritis - Marketscreener.com
Enlivex Therapeutics Ltd. Hosts Investor Webinar to Discuss Positive Interim Data from Allocetra™ Osteoarthritis Trial - Nasdaq
Can Enlivex's Allocetra Transform Osteoarthritis Treatment? 47% Pain Reduction Reported - StockTitan
Enlivex Therapeutics (NASDAQ:ENLV) Given Buy Rating at D. Boral Capital - Defense World
Enlivex Announces Positive Interim Data From Early Stage Trial For Osteoarthritis Treatment - Nasdaq
Enlivex Reports Promising Interim Results in Knee Osteoarthritis Trial - TipRanks
Enlivex Announces Positive Interim DataStatistically Significant 47.0% Durable and Persistent Pain Reduction At Six Months, in Patients with Moderate to Severe Knee Osteoarthritis - The Manila Times
Enlivex Therapeutics Reports Positive Interim Results in Phase I/II Trial of Allocetra™ for Knee Osteoarthritis - Nasdaq
Can Enlivex's Osteoarthritis Treatment Disrupt a Multi-Billion Dollar Market? 6-Month Data Impresses - StockTitan
Press Release Distribution & PR Platform - ACCESS Newswire
We're Keeping An Eye On Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Rate - Simply Wall St
Enlivex Advances Immunotherapy with Japanese Patent for Osteoarthritis Treatment - PUNE.NEWS
Enlivex Therapeutics (NASDAQ:ENLV) Hails Positive Trial Results for Allocetra Treatment of Knee Osteoarthritis - Markets Insider
Enlivex Therapeutics Starts Phase II Allocetra Trail to Treat Knee Osteoarthritis - Markets Insider
Enlivex Wins Key Patent in Japan for Osteoarthritis Treatment - Markets Insider
엔라이벡스 (ENLV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
3.66%
자본화:
|
볼륨(24시간):